Related Experiment Video

Updated: May 1, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:45

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

483

Oligonucleotide-based therapy for neurodegenerative diseases

Iddo Magen1, Eran Hornstein1

  • 1Department of Molecular Genetics, Faculty of Biochemistry, Weizmann Institute of Science, Rehovot, Israel.

Brain Research
|April 15, 2014
PubMed

Insights

Oligonucleotide-based therapies offer new treatments for neurodegenerative diseases by targeting RNA. These advanced therapies show promise for preserving brain health and function.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Neurodegenerative diseases like Alzheimer's, Parkinson's, Huntington's, and ALS involve complex molecular genetic pathways.
  • Current research focuses on intervening in neurotoxic gene activity or activating neuroprotective mechanisms.

Purpose of the Study:

  • To review recent advancements in oligonucleotide-based therapies for neurodegenerative conditions.
  • To assess the potential of RNA-targeting oligonucleotide technologies for future therapeutic applications.

Main Methods:

  • Literature review of recent studies on oligonucleotide technologies.
  • Analysis of therapeutic strategies targeting RNA in neurodegenerative disease models.

Main Results:

  • Oligonucleotide-based therapies are emerging as a significant strategy in drug development.
  • These technologies demonstrate potential for direct interference with disease-causing genes or pathways.

Conclusions:

  • Oligonucleotide technologies targeting RNA represent a promising frontier for developing novel treatments for neurodegenerative diseases.
  • These approaches are expected to contribute to the preservation of brain integrity.
Keywords:
Antisense oligonucleotidesDeliveryNeurodegenerationRNA interferencemicroRNAsiRNA

More Related Videos

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

18.4K
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

61.2K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
13.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K